Jul 25, 2024 09:02AM
Jul 25, 2024 09:00AM
Jun 4, 2024 07:03AM
Jun 4, 2024 07:00AM
May 29, 2024 04:01PM
May 7, 2024 07:03AM
May 6, 2024 06:00AM GlycoMimetics (GLYC) Reports Results of Phase 3 Study of Uproleselan in RR and AML
May 6, 2024 06:00AM
Mar 27, 2024 07:00AM
Jan 4, 2024 07:02AM
Jan 4, 2024 07:00AM
Jan 3, 2024 07:00AM
Dec 10, 2023 12:00PM
Nov 3, 2023 07:00AM GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023
Aug 2, 2023 07:00AM
Jun 15, 2023 08:03AM
Jun 15, 2023 08:00AM
Mar 29, 2023 07:00AM
Feb 15, 2023 08:01AM
Feb 15, 2023 08:00AM
Dec 12, 2022 07:00AM GlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia presented at ASH Annual Meeting
Nov 9, 2022 07:00AM
Nov 3, 2022 09:00AM
Sep 6, 2022 07:00AM
Aug 3, 2022 07:00AM
Apr 28, 2022 07:30AM
Mar 3, 2022 07:30AM
Mar 2, 2022 09:15AM GlycoMimetics Appoints Deepak Tiwari, Ph.D., as new Vice President, Technical Operations
Feb 23, 2022 04:30PM
Feb 23, 2022 04:00PM
Dec 13, 2021 09:00AM
Dec 6, 2021 09:15AM
Nov 23, 2021 04:30PM
Nov 22, 2021 04:15PM
Nov 15, 2021 07:00AM GlycoMimetics Completes Enrollment of Phase 3 Registration Trial Evaluating Lead Candidate Uproleselan in Patients with Relapsed /Refractory Acute Myeloid Leukemia (AML)
Nov 11, 2021 09:00AM
Nov 2, 2021 07:30AM
Sep 23, 2021 04:00PM
Sep 23, 2021 04:00PM
Aug 9, 2021 09:00AM
Aug 5, 2021 07:30AM
Aug 4, 2021 05:18PM GlycoMimetics (GLYC) Appoints Harout Semerjian as new CEO
Aug 4, 2021 04:15PM
Jul 22, 2021 09:00AM
Jul 12, 2021 09:00AM
May 26, 2021 09:00AM
May 3, 2021 07:30AM
May 3, 2021 07:30AM
Apr 12, 2021 06:11AM GlycoMimetics (GLYC) Reports Positive Findings From Phase 1b Trial of GMI-1359
Apr 10, 2021 09:00AM

322,094 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All